UBS Group’s Sinovac Biotech, Ltd SVA Stock Holding History

UBS Group’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-200	Closed	-$1K	–	10256
2014 Q4	$1K	Buy	+200	New	+$1.02K	﹤0.01%	9654

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

UBS Group's SVA Position: Q2 2026 in Review

UBS Group increased its Sinovac Biotech, Ltd (SVA) stake by 11% in Q2 2026, buying an estimated $1.62K and bringing the position to 2,479 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #8295.

UBS Group first reported a position in SVA in Q4 2014 and has held it in 38 quarters since. The position peaked at $66K in Q1 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

UBS Group held 2,479 shares of Sinovac Biotech, Ltd worth $16K as of Q2 2026.
UBS Group bought 250 Sinovac Biotech, Ltd shares in Q2 2026, an estimated $1.62K.
Sinovac Biotech, Ltd made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8295 holding.
UBS Group first reported a position in Sinovac Biotech, Ltd in Q4 2014 and has held it in 38 quarters since.
UBS Group's Sinovac Biotech, Ltd position peaked at $66K in Q1 2018.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.